Stocktoria
Lite Strategy, Inc. LITS
Lite Strategy, Inc. (LITS) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 38.16% (safety: no dividend).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 2081 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.119 |
| Retained earnings / assets | -11.134 |
| EBIT / assets | -1.559 |
| Equity / liabilities | 38.936 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LITS | Lite Strategy, Inc. | 1/9 | -5.11 | — | -100% |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
FAQ
Is LITS financially healthy?
Lite Strategy, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does LITS pay a dividend, and is it safe?
Yes. Lite Strategy, Inc. pays a dividend yielding about 38.16% with a None payout ratio, rated “no dividend” for safety.
How profitable is LITS?
In FY2026, Lite Strategy, Inc. had a return on equity of -170.9%.
Is LITS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Lite Strategy, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone, a dividend yield of 38.16%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-06-30. Facts plus Stocktoria's own computed scores — not investment advice.